Meglitinide

This classification denotes an anti-diabetic agent with the molecular formula C17H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8V6OK1I088, chemically known as benzoic acid, 4-(2-((5-chloro-2-methoxybenzoyl)amino)ethyl)- but more generally known as meglitinide, which bears US NIH Compound Identifier 41214. European Medicines Agency schedules Meglitinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08713MIG. The term MEGLITINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). MEGLITINIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule meglitinide under HS 29242995 and SITC 51479. As of Q4 2014, MEGLITINIDE remains US FDA's Preferred Term for this commodity. Meglitinide bears US NLM identifiers UMLS ID C0065880 and NCI Concept Code C66075. SMILES: CLC1CC(C(=O)NCCC2CCC(CC2)C(=O)O)C(OC)CC1.